vs

Side-by-side financial comparison of Arcutis Biotherapeutics, Inc. (ARQT) and TOMPKINS FINANCIAL CORP (TMP). Click either name above to swap in a different company.

TOMPKINS FINANCIAL CORP is the larger business by last-quarter revenue ($194.8M vs $129.5M, roughly 1.5× Arcutis Biotherapeutics, Inc.). TOMPKINS FINANCIAL CORP runs the higher net margin — 49.4% vs 13.4%, a 36.0% gap on every dollar of revenue. On growth, TOMPKINS FINANCIAL CORP posted the faster year-over-year revenue change (152.7% vs 81.5%). Over the past eight quarters, Arcutis Biotherapeutics, Inc.'s revenue compounded faster (104.9% CAGR vs 63.6%).

Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies for immune-mediated dermatological diseases. Its core product portfolio targets conditions including psoriasis, atopic dermatitis, and alopecia areata, primarily serving patients and healthcare providers across the United States, addressing unmet needs in the dermatology care segment.

Tompkins Financial Corporation is a small, diversified financial services company based in Ithaca, New York. It is the parent of the Tompkins Trust Company, as well as several other banks, an insurance agency, and a wealth management division.

ARQT vs TMP — Head-to-Head

Bigger by revenue
TMP
TMP
1.5× larger
TMP
$194.8M
$129.5M
ARQT
Growing faster (revenue YoY)
TMP
TMP
+71.2% gap
TMP
152.7%
81.5%
ARQT
Higher net margin
TMP
TMP
36.0% more per $
TMP
49.4%
13.4%
ARQT
Faster 2-yr revenue CAGR
ARQT
ARQT
Annualised
ARQT
104.9%
63.6%
TMP

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
ARQT
ARQT
TMP
TMP
Revenue
$129.5M
$194.8M
Net Profit
$17.4M
$96.2M
Gross Margin
91.0%
Operating Margin
14.2%
71.7%
Net Margin
13.4%
49.4%
Revenue YoY
81.5%
152.7%
Net Profit YoY
388.9%
EPS (diluted)
$0.13
$6.72

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARQT
ARQT
TMP
TMP
Q2 26
$129.5M
Q4 25
$129.5M
$194.8M
Q3 25
$99.2M
$87.4M
Q2 25
$81.5M
$82.6M
Q1 25
$65.8M
$81.7M
Q4 24
$71.4M
$77.1M
Q3 24
$44.8M
$76.6M
Q2 24
$30.9M
$72.7M
Net Profit
ARQT
ARQT
TMP
TMP
Q2 26
$17.4M
Q4 25
$17.4M
$96.2M
Q3 25
$7.4M
$23.7M
Q2 25
$-15.9M
$21.5M
Q1 25
$-25.1M
$19.7M
Q4 24
$-10.8M
$19.7M
Q3 24
$-41.5M
$18.6M
Q2 24
$-52.3M
$15.7M
Gross Margin
ARQT
ARQT
TMP
TMP
Q2 26
91.0%
Q4 25
91.0%
Q3 25
91.2%
Q2 25
90.8%
Q1 25
86.6%
Q4 24
90.3%
Q3 24
87.7%
Q2 24
88.8%
Operating Margin
ARQT
ARQT
TMP
TMP
Q2 26
14.2%
Q4 25
14.2%
71.7%
Q3 25
8.6%
35.6%
Q2 25
-17.9%
34.2%
Q1 25
-37.3%
31.6%
Q4 24
-10.7%
33.4%
Q3 24
-87.3%
32.0%
Q2 24
-162.3%
28.3%
Net Margin
ARQT
ARQT
TMP
TMP
Q2 26
13.4%
Q4 25
13.4%
49.4%
Q3 25
7.5%
27.1%
Q2 25
-19.5%
26.0%
Q1 25
-38.1%
24.1%
Q4 24
-15.1%
25.5%
Q3 24
-92.8%
24.3%
Q2 24
-169.6%
21.6%
EPS (diluted)
ARQT
ARQT
TMP
TMP
Q2 26
$0.13
Q4 25
$0.14
$6.72
Q3 25
$0.06
$1.65
Q2 25
$-0.13
$1.50
Q1 25
$-0.20
$1.37
Q4 24
$-0.09
$1.39
Q3 24
$-0.33
$1.30
Q2 24
$-0.42
$1.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARQT
ARQT
TMP
TMP
Cash + ST InvestmentsLiquidity on hand
$42.9M
$132.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$189.5M
$938.4M
Total Assets
$433.0M
$8.7B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARQT
ARQT
TMP
TMP
Q2 26
$42.9M
Q4 25
$42.9M
$132.8M
Q3 25
$47.1M
$193.5M
Q2 25
$72.7M
$212.6M
Q1 25
$53.1M
$193.1M
Q4 24
$71.3M
$134.4M
Q3 24
$134.9M
$132.3M
Q2 24
$84.3M
$70.9M
Total Debt
ARQT
ARQT
TMP
TMP
Q2 26
Q4 25
$109.0M
Q3 25
$108.5M
Q2 25
$108.0M
Q1 25
$107.6M
Q4 24
$107.2M
Q3 24
$204.6M
Q2 24
$203.8M
Stockholders' Equity
ARQT
ARQT
TMP
TMP
Q2 26
$189.5M
Q4 25
$189.5M
$938.4M
Q3 25
$158.1M
$788.8M
Q2 25
$139.0M
$761.8M
Q1 25
$142.7M
$741.4M
Q4 24
$157.5M
$713.4M
Q3 24
$156.6M
$719.9M
Q2 24
$186.4M
$674.6M
Total Assets
ARQT
ARQT
TMP
TMP
Q2 26
$433.0M
Q4 25
$433.0M
$8.7B
Q3 25
$371.0M
$8.5B
Q2 25
$352.4M
$8.4B
Q1 25
$344.1M
$8.2B
Q4 24
$348.9M
$8.1B
Q3 24
$437.4M
$8.0B
Q2 24
$444.8M
$7.9B
Debt / Equity
ARQT
ARQT
TMP
TMP
Q2 26
Q4 25
0.58×
Q3 25
0.69×
Q2 25
0.78×
Q1 25
0.75×
Q4 24
0.68×
Q3 24
1.31×
Q2 24
1.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARQT
ARQT
TMP
TMP
Operating Cash FlowLast quarter
$38.9M
Free Cash FlowOCF − Capex
$31.9M
FCF MarginFCF / Revenue
16.4%
Capex IntensityCapex / Revenue
3.6%
Cash ConversionOCF / Net Profit
0.40×
TTM Free Cash FlowTrailing 4 quarters
$105.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARQT
ARQT
TMP
TMP
Q2 26
Q4 25
$26.2M
$38.9M
Q3 25
$-1.8M
$34.9M
Q2 25
$324.0K
$18.9M
Q1 25
$-30.4M
$22.2M
Q4 24
$-748.0K
$95.0M
Q3 24
$-34.7M
$21.2M
Q2 24
$-45.1M
$27.3M
Free Cash Flow
ARQT
ARQT
TMP
TMP
Q2 26
Q4 25
$31.9M
Q3 25
$33.9M
Q2 25
$246.0K
$18.3M
Q1 25
$-31.0M
$20.9M
Q4 24
$88.8M
Q3 24
$-34.8M
$18.9M
Q2 24
$26.3M
FCF Margin
ARQT
ARQT
TMP
TMP
Q2 26
Q4 25
16.4%
Q3 25
38.8%
Q2 25
0.3%
22.1%
Q1 25
-47.1%
25.5%
Q4 24
115.1%
Q3 24
-77.8%
24.7%
Q2 24
36.2%
Capex Intensity
ARQT
ARQT
TMP
TMP
Q2 26
Q4 25
0.0%
3.6%
Q3 25
0.0%
1.1%
Q2 25
0.1%
0.8%
Q1 25
0.9%
1.7%
Q4 24
0.0%
8.1%
Q3 24
0.3%
2.9%
Q2 24
0.0%
1.3%
Cash Conversion
ARQT
ARQT
TMP
TMP
Q2 26
Q4 25
1.51×
0.40×
Q3 25
-0.24×
1.47×
Q2 25
0.88×
Q1 25
1.13×
Q4 24
4.82×
Q3 24
1.14×
Q2 24
1.74×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons